Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Jnj save search
American Lung Association and LUNGevity Foundation Announce $3 Million Research Partnership to Intercept Lung Cancer
Published: 2024-04-09 (Crawled : 11:00) - biospace.com/
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -0.3%
H: 0.0%
C: 0.0%
partnership lung association million cancer research foundation
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
NBTX | $5.59 -8.21% -10.73% 24K
|
Manufacturing
|
| O: 3.11%
H: 1.19%
C: -2.54%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
lung cancer treatment
Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -0.28%
H: 0.27%
C: 0.04%
cancer therapy
RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson's ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
Published: 2024-03-18 (Crawled : 12:00) - prnewswire.com
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.2%
H: 0.08%
C: -1.14%
rybrevant lung cancer cell care
World Cancer Immunotherapy Market Research 2023-2027: Curing Cancer is Generating Enormous New Opportunities - Outcome Potential, Technology Environment, Target Solutions
Published: 2024-03-16 (Crawled : 04:20) - prnewswire.com
BIIB | $196.8 -0.7% -0.72% 980K
|
Health Technology
| Email alert
Add to watchlist
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
| Email alert
Add to watchlist
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
| Email alert
Add to watchlist
world cancer research solutions immunotherapy technology market
Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer
Published: 2024-03-14 (Crawled : 08:00) - prnewswire.com
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: 0.0%
cancer treat series cell
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
| Email alert
Add to watchlist
rybrevant fda first lung approved cancer cell treatment therapy
Liquid Biopsy Market Set to Reach US$ 10.08 Billion by 2030 with Pioneering Breakthroughs in Cancer Detection and Management
Published: 2024-02-16 (Crawled : 19:00) - prnewswire.com
TMO | $557.87 -1.3% -0.24% 860K
|
Health Technology
| Email alert
Add to watchlist
EXAS | $65.35 -8.4% -9.17% 2.7M
|
Health Technology
| Email alert
Add to watchlist
QGEN | $39.67 -1.27% 0.0% 550K
|
Health Technology
| Email alert
Add to watchlist
QGEN | $39.67 -1.27% 0.0% 550K
|
Health Technology
| Email alert
Add to watchlist
LH | $203.32 -1.17% 0.0% 670K
|
Health Services
| Email alert
Add to watchlist
ILMN | $121.16 -4.65% -4.86% 1.2M
|
Health Technology
| Email alert
Add to watchlist
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
| Email alert
Add to watchlist
management reach cancer set market
FDA Decisions: First Frontline Pancreatic Cancer Treatment Approved in More t...
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
PRGO A | $30.13 -0.63% 0.03% 1.7M
|
Health Technology
|
| O: 0.67%
H: 2.06%
C: 1.86%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
ABT | $108.89 -0.2% 0.28% 3.4M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
fda first approved cancer pancreatic treatment
FDA Decisions: First Frontline Pancreatic Cancer Treatment Approved in More than a Decade
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
PRGO A | $30.13 -0.63% 0.03% 1.7M
|
Health Technology
|
| O: 0.67%
H: 2.06%
C: 1.86%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
ABT | $108.89 -0.2% 0.28% 3.4M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
fda first approved cancer pancreatic treatment
Prevention and Treatment of Prostate Cancer: Global Market for Prostate Cancer Screening and Detection is Projected to Grow at a CAGR of 5.8% to Reach $19.8 billion by 2028
Published: 2024-02-09 (Crawled : 15:30) - prnewswire.com
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 1.11%
H: 0.0%
C: 0.0%
reach cancer treatment global market
Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.48 -8.41% 43.47% 22
|
Health Technology
|
| O: -1.53%
H: 0.0%
C: 0.0%
AZNCF | $135.94 -2.12% -4.19% 770
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
UCBJY | $63.0 -1.37% -4.38% 11K
|
Manufacturing
|
| O: 1.71%
H: 1.28%
C: 0.94%
ALPMY | $9.2715 -2.92% -1.11% 500K
|
Manufacturing
|
| O: 0.28%
H: 0.18%
C: 0.0%
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 0.07%
H: 0.42%
C: 0.07%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 0.09%
H: 0.39%
C: -0.36%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
BMY | $48.51 0.48% 0.19% 9.8M
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.12%
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: 1.48%
H: 0.0%
C: 0.0%
VRTX | $397.36 0.2% 0.23% 1.1M
|
Health Technology
|
| O: 0.15%
H: 2.4%
C: 0.56%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
JAZZ | $110.91 0.3% 0.29% 600K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -1.4%
AZN | $68.73 -0.29% -0.26% 7.1M
|
Health Technology
|
| O: -0.4%
H: 0.19%
C: -0.33%
AMGN | $265.51 -0.66% -0.67% 1.2M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: -6.22%
report cancer blood growth market
Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU
Published: 2024-01-24 (Crawled : 14:30) - biospace.com/
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
asco bladder cancer treatment
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
Published: 2024-01-23 (Crawled : 11:01) - prnewswire.com
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -1.11%
H: 0.0%
C: 0.0%
million cancer series therapeutics
FDA Decisions: J&J's Bladder Cancer Drug Wins Full Approval
Published: 2024-01-22 (Crawled : 14:30) - biospace.com/
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: -0.15%
PRGO A | $30.13 -0.63% 0.03% 1.7M
|
Health Technology
|
| O: 0.36%
H: 2.11%
C: 1.29%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
ABT | $108.89 -0.2% 0.28% 3.4M
|
Health Technology
|
| O: 0.88%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
fda drug approval bladder cancer
J&J Secures Full FDA Approval for Bladder Cancer Drug Balversa
Published: 2024-01-22 (Crawled : 13:30) - biospace.com/
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
fda drug approval bladder cancer balversa
U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
Published: 2024-01-19 (Crawled : 21:00) - prnewswire.com
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
| Email alert
Add to watchlist
balversa drug genetic approval food bladder cancer treat grants advanced
FDA Decisions: Merck's Keytruda Wins 39th Overall Approval, Third in Cervical Cancer
Published: 2024-01-15 (Crawled : 17:00) - biospace.com/
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
| Email alert
Add to watchlist
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
| Email alert
Add to watchlist
PRGO A | $30.13 -0.63% 0.03% 1.7M
|
Health Technology
| Email alert
Add to watchlist
ABT | $108.89 -0.2% 0.28% 3.4M
|
Health Technology
| Email alert
Add to watchlist
fda cancer keytruda
Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-12-21 (Crawled : 13:00) - prnewswire.com
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -1.87%
H: 0.0%
C: 0.0%
rybrevant fda lung drug license approval cancer cell treatment application plus
Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight
Published: 2023-12-20 (Crawled : 22:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -1.87%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.21%
H: 0.63%
C: 0.1%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
cancer growth study market
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.